Head & Neck · 2019 · 27 citations · 17 references
PharmacyPharmacologyPharmacotherapyCancer PharmacologyOncology PharmacotherapyPharmacokinetics Of Anticancer AgentsCancer ImmunotherapyDose Adjustment In OncologyDosing Of Immuno-oncology AgentsPharmacokinetics Of Anticancer DrugsTargeted Therapy PharmacokineticsToxicity ManagementCetuximab TherapyDose Cohort ExpansionExpansion Cohort DesignMetastatic Squamous Cell CarcinomaPartial Response AssessmentPi3k InhibitorsPilot Study DesignTreatment Dosing Regimens
BACKGROUND: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). METHODS: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparlisib starting day 7 and daily thereafter. The dose of buparlisib was escalated in a 3 + 3 design followed by a dose expansion cohort of 6 patients. The MTD of buparlisib per protocol was 100 mg daily with cetuximab given intravenously every 14 days starting day 0. RESULTS: Ten patients had ≥2 previous treatment regimens (11 with prior cetuximab). There were no dose limiting toxicities observed during dose escalation. One patient achieved a partial response and 4 achieved stable disease. CONCLUSION: Based on this pilot study, buparlisib at 100 mg daily plus cetuximab proved to be well-tolerated. Patients previously treated with cetuximab monotherapy showed benefit from this combination.
17
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations
Medicine, Oncology, Pharmacotherapy +13